Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy-Reference-Cited by-同舟云学术

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy

Published:2020-07 Issue:4 Volume:21 Page:357-364.e7
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Arnold Susanne M.^ORCID,Chansky Kari,Baggstrom Maria Q.,Thompson Michael A.^ORCID,Sanborn Rachel E.,Villano John L.,Waqar Saiama N.,Hamm John^ORCID,Leggas Markos^ORCID,Willis Maurice,Rosales Joseph,Crowley John J.

Funder

Onyx Pharmaceuticals

Amgen

Cancer Research and Biostatistics

Amgen Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan;Perez-Soler;J Clin Oncol,1996

2. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

3. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer;Fukuoka;J Clin Oncol,1992

4. Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer;Masuda;Clin Lung Cancer,2010

5. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT);Le Chevalier;Proceedings of ASCO,1997

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics;Genes;2024-05-27

2. Nanomedicine Combats Drug Resistance in Lung Cancer;Advanced Materials;2023-11-27

3. Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review;Clinical Lung Cancer;2023-05

4. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma;Scientific Reports;2023-03-17

5. Systematically integrative analysis identifies diagnostic and prognostic candidates and small-molecule drugs for lung adenocarcinoma;Translational Cancer Research;2021-08